Articles

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Record identifier

TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Full title

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Publisher

Australia: John Wiley & Sons, Inc

Journal title

Clinical & translational immunology, 2021, Vol.10 (3), p.e1257-n/a

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

Language

English

Formats

Publication information

Publisher

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

OTHER IDENTIFIERS

ISSN

E-ISSN

DOI

How to access this item

Online

1 item

How to access?

Login with a Library card